Research Article

The Wnt Co-Receptor Lrp6 Is Required for Normal Mouse Mammary Gland Development

  • Charlotta Lindvall mail, (CL); (BW)

    Affiliation: Laboratory of Cell Signaling and Carcinogenesis, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Cassandra R. Zylstra,

    Affiliation: Laboratory of Cell Signaling and Carcinogenesis, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Nicole Evans,

    Affiliation: Laboratory of Cell Signaling and Carcinogenesis, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Richard A. West,

    Affiliation: Flow Cytometry, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Karl Dykema,

    Affiliation: Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Kyle A. Furge,

    Affiliation: Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Bart O. Williams mail (CL); (BW)

    Affiliation: Laboratory of Cell Signaling and Carcinogenesis, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

  • Published: June 05, 2009
  • DOI: 10.1371/journal.pone.0005813


Canonical Wnt signals are transduced through a Frizzled receptor and either the LRP5 or LRP6 co-receptor; such signals play central roles during development and in disease. We have previously shown that Lrp5 is required for ductal stem cell activity and that loss of Lrp5 delays normal mammary development and Wnt1-induced tumorigenesis. Here we show that canonical Wnt signals through the Lrp6 co-receptor are also required for normal mouse mammary gland development. Loss of Lrp6 compromises Wnt/β-catenin signaling and interferes with mammary placode, fat pad, and branching development during embryogenesis. Heterozygosity for an inactivating mutation in Lrp6 is associated with a reduced number of terminal end buds and branches during postnatal development. While Lrp6 is expressed in both the basal and luminal mammary epithelium during embryogenesis, Lrp6 expression later becomes restricted to cells residing in the basal epithelial layer. Interestingly, these cells also express mammary stem cell markers. In humans, increased Lrp6 expression is associated with basal-like breast cancer. Taken together, our results suggest both overlapping and specific functions for Lrp5 and Lrp6 in the mammary gland.


Wnt signaling plays key roles in embryogenesis and in adult tissue homeostasis of metazoan animals [1]. The extracellular Wnt signal stimulates numerous intracellular signal transduction cascades, including the canonical Wnt/β-catenin pathway, which regulates gene expression in the nucleus, and a number of noncanonical pathways, which regulate many other aspects of cell biology including cell migration, adhesion, and polarity [2][4]. Mutations of the genes involved in Wnt signaling cause congenital defects in humans, and inappropriate activation of the Wnt/β-catenin pathway has been linked to the development of human cancer [5][7]. An increasing number of studies have shown that Wnt/β-catenin signaling regulates the self-renewal and differentiation of adult stem cells, raising the possibility that this process is subverted in cancer [8][10].

Activation of the Wnt/β-catenin pathway is initiated by the binding of Wnt proteins to cell surface receptors composed of a member of the Frizzled (Fzd) protein family and one of the two low-density lipoprotein receptor–related proteins, LRP5 or LRP6 (reviewed in [11]). Signaling from Wnt receptors leads to inactivation of a cytoplasmic protein complex that normally catalyzes the phosphorylation and subsequent destruction of β-catenin. Canonical Wnt signaling thus induces stabilization of cytosolic β-catenin. A fraction of β-catenin then enters the nucleus, binds to transcription factors such as those of the LEF-1/TCF family, and modulates the transcription of specific target genes (see The Wnt Homepage at​w.html).

The initiation of canonical Wnt/β-catenin signaling requires LRP5 or LRP6 [12][14]; in contrast, noncanonical Wnt pathways are usually independent of these two proteins [3], [4]. LRP5 and LRP6 are highly homologous and exhibit functional redundancy both in vitro and in vivo [14][17]. However, loss-of-function studies in animals show that Lrp5 and Lrp6 also have unique roles for which the other cannot compensate. In mice, disruption of Lrp6 causes severe developmental defects [13]. The defects reflect a composite of some of the Wnt mutant phenotypes and include a deletion of caudal midbrain, axis truncation, and limb patterning defects. Neonatal lethality prevents a thorough analysis of the consequences of Lrp6 deficiency in the adult mouse. Disruption of Lrp5 does not cause gross developmental abnormalities, but abnormalities have been identified in a number of different tissues [17][20]. We have previously shown that Lrp5 is required for ductal stem cell activity, which is apparent by the failure of Lrp5−/− mammary epithelial cells to colonize in transplantation experiments [21]. Consequently, loss of Lrp5 is associated with delayed mammary gland development and Wnt1-induced tumorigenesis [21]. Here we show that canonical Wnt signals through the Lrp6 co-receptor are also required for normal mammary gland development.


Lrp6 expression in the mammary gland

The targeting vector used to create the Lrp6−/− mouse strain contained the β-galactosidase-gal) gene. As a result, β-gal expression is directed from the Lrp6 promoter in Lrp6+/− and Lrp6−/− mice and can be used as a surrogate marker for Lrp6 expression [13]. Several substrates are available to detect β-gal, including 5-bromo-4-chloro-3-indolyl-β-D-galactopy​ranoside(X-gal) and 9H-(1,3-dichloro-9,9-dimethylacridin-2-one​-7-yl)-β-D-galactopyranoside(DDAOG).

In order to determine the expression pattern of Lrp6 in the mammary gland, we first stained mammary whole mounts from Lrp6+/− and Lrp6+/+ females of different ages (newborn, juvenile 5-week, adult 12-week, and days 12.5 and 18.5 of pregnancy) with X-gal. β-gal expression was detected in the Lrp6+/− mammary epithelium, stroma, and fat pad at all analyzed time points (Fig. 1A–B and data not shown). However, the expression pattern differed between mammary glands collected from newborn females versus glands collected from juvenile, adult, and pregnant females. The mammary epithelium contains a basal cell layer of mostly myoepithelial cells and a luminal cell layer of keratin 8/18–positive epithelial cells. During embryogenesis and until a few days after birth, β-gal expression was detected in both the basal and luminal mammary epithelium (Fig. 1A). In juvenile, adult, and pregnant females, however, β-gal expression was primarily seen in cells residing within the basal epithelial cell layer of mammary glands (Fig. 1B). Abundant Lrp6 expression was seen in the mammary fat pad at all developmental time points analyzed (Fig. 1A–B and data not shown). Lrp6+/+ mammary whole mounts were used as a negative control for the X-gal staining (Fig. 1A–B).


Figure 1. Expression pattern of Lrp6 in the mammary gland.

β-gal expression directed from the Lrp6 promoter in Lrp6+/− mice was used as a surrogate marker for Lrp6 expression. We used the β-gal substrates X-gal and DDAOG to identify cells that express Lrp6. Shown in (A-B) are X-gal-stained mammary whole mounts and 5-µm sections from 2-day-old (A) and 12-week-old (B) female mice. (A) Lrp6 promoter-driven β-gal expression is visible as blue staining in both the basal and luminal mammary epithelium and in the mammary fat pad of newborn mice. (B) In older mice, β-gal-expressing cells are primarily identified within the basal epithelial cell layer and in the mammary fat pad. The arrows indicate typical cells that stained blue with X-gal. No staining was detected in Lrp6+/+ mammary glands, which were used as negative controls for X-gal staining. (C-F) Representative FACS results of DDAOG-stained and CD24/CD49f antibody–labeled mammary epithelial cells. The β-gal-cleaved product of DDAOG has far-red fluorescence and was used to detect cells with Lrp6 promoter–driven β-gal expression. (C) The luminal and basal cell compartments are marked by pink and blue dashed lines, respectively. (D) 80% of the DDAOG-positive cells are found within the basal epithelial cell compartment. (E-F) DDAOG gating strategy. The DDAOG gate is indicated by the black line. The Lrp6+/− sample (E) has 0.33% DDAOG-positive cells; the Lrp6+/+ negative control sample (F) has 0.01% DDAOG-positive cells.


To further characterize the expression pattern of Lrp6 in the adult mammary epithelium, we performed fluorescence-activated cell sorting (FACS) analysis on single-cell suspensions isolated from mammary glands of 3-month-old Lrp6+/− and Lrp6+/+ females. Because hematopoietic and stromal cells can make up at least 50% of such cell suspensions, we first removed cells expressing cell surface antigens of hematopoietic and endothelial origin (CD45, Ter119, and CD31). The epithelial cell–enriched fractions were then labeled with the CD24 (heat-stable antigen) and CD49f (α6 integrin) cell surface antigens. We used the fluorescent β-gal substrate DDAOG [22] to detect cells that express Lrp6. The basal and luminal epithelial subpopulations, as well as a cell fraction enriched for mammary stem cells, can be visualized by the relative expression of CD24 and CD49f [23], [24] (Fig. 1C). In concordance with the X-gal staining, we found by FACS that the majority of DDAOG-positive cells resided in the basal subpopulation (Fig. 1D). These DDAOG-positive cells expressed the highest levels of CD49f and moderate levels of CD24 (Fig. 1C–D). This observation was of particular interest because mammary epithelial cells with stem cell properties typically exhibit this expression pattern [23]. Lrp6+/+ mammary epithelial cells were used as a negative control for the DDAOG staining (Fig. 1F).

Impaired mammary development in Lrp6−/− embryos

Lrp6−/− mice die shortly after birth. To determine the effect of Lrp6 deficiency on the rudimentary mammary gland that develops by birth, we collected ventral skin from Lrp6−/− (n = 5) and Lrp6+/+ (n = 10) embryos at E18.5. Normally at this stage, the mammary gland is composed of a ductal tree consisting of a primary duct with secondary and tertiary branches surrounded by a fat pad. We found that the while all 10 mammary glands were present in Lrp6−/− embryos, they were underdeveloped. The nipples were considerably smaller than those of littermate controls and the mammary epithelium typically consisted of a single duct (Fig. 2A). In a minority of inguinal Lrp6−/− mammary glands, the epithelium formed two short branches at the extremity of the main duct (not shown). During dissection and carmine staining we noticed that the adipose tissue forming the fat pad was abnormally small and underdeveloped in Lrp6−/− embryos (Fig. 2B). In contrast, all Lrp6+/+ mammary glands showed secondary and tertiary branches surrounded by a fat pad (Fig. 2A–B).


Figure 2. Lrp6 is required for embryonic mammary development.

(A) Carmine-stained skin pads of inguinal mammary glands at E18.5. While in the Lrp6+/+ mammary gland the nipple, rudimentary ductal tree, and fat pad are all normally developed, the Lrp6−/− mammary gland contains a small nipple, a single ductal out-growth, and an abnormally small fat pad. Dashed lines indicate inguinal epithelium. (B) Oil red O staining of mammary fat pads from Lrp6+/+ and Lrp6−/− embryos. The Lrp6−/− fat pad is abnormally small compared to that of the littermate control. Scale bar: 0.5 mm. (C-D) X-gal-stained BAT-gal embryo whole mounts (C) and histology sections of mammary placode (D) at E12.5. Cells expressing BAT-gal are stained blue. (C) X-gal stains the mammary placodes of BAT-gal;Lrp6+/+ embryos dark blue. Arrow heads indicate mammary placodes number 2, 3, 4, and 5. Mammary placodes are not readily visible on X-gal-stained BAT-gal;Lrp6−/− embryo whole mounts. (D) On the histological level, the mammary placodes of BAT-gal;Lrp6−/− embryos are significantly smaller and exhibit fewer cells with BAT-gal expression than the mammary placodes of littermate controls. Dashed lines indicate inguinal placodes.


The ductal tree at E18.5 evolves from the epithelial mammary placode, which has formed by E12.5. To determine whether Lrp6-mediated Wnt signaling is required for the development of mammary placodes, we analyzed Lrp6−/− and Lrp6+/+ littermate whole embryos at E12.5. To assess the activity of Wnt/β-catenin signaling pathway in this context, we intercrossed Lrp6+/− mice to BAT-gal transgenic mice. BAT-gal mice carry a reporter gene which contains a β-gal gene under the transcriptional control of LEF/TCF sites [25]. It is important to note that β-gal expression induced by BAT-gal reporter gene activity can be discriminated from β-gal expression induced by Lrp6 promoter activity due to a large difference in the time it takes to detect the β-gal by X-gal staining. While BAT-gal-associated β-gal expression is detected within 20 minutes of X-gal staining, Lrp6-associated β-gal expression is not detected until after several hours of X-gal staining. Our results showed that loss of Lrp6 compromised Wnt/β-catenin signaling in the developing mammary placodes and interfered with their formation. BAT-gal reporter gene activity was significantly reduced in Lrp6−/− embryos relative to littermate controls (Fig. 2C). On the histological level, the mammary placodes of Lrp6−/− embryos were significantly smaller and contained fewer cells with reporter gene activity (Fig. 2D).

Postnatal mammary development in Lrp6+/− females

To determine if the loss of one allele affects postnatal mammary development, we collected and examined inguinal mammary whole mounts from juvenile (5-week) and adult (11-week) Lrp6+/− and Lrp6+/+ female littermates. No differences in ductal extension were found at 5 weeks (Fig. 3A). However, the number of terminal end buds (TEBs) was significantly reduced in Lrp6+/− mammary glands (Fig. 3A–B). TEBs are club-shaped epithelial thickenings at the distal ends of growing ducts and are the sites of the most rapid cell proliferation. We found that the number of TEBs was reduced by 33% in juvenile Lrp6+/− mice compared with littermate wild-type mice (p = 1.3×10−6). The branching complexity in adult mice is a function of terminal end bud activity during juvenile ductal extension. Morphometric analysis showed that the branching complexity of 11-week-old Lrp6+/− glands was decreased by 17% compared with that of littermate wild-type mice (p = 8.4×10−3) (Fig. 3C). We measured the weight of Lrp6+/− and Lrp6+/+ mammary fat pads but no difference was detected (data not shown).


Figure 3. Haploinsufficiency for Lrp6 in postnatal mammary development.

(A) Representative mammary whole-mount preparations are shown for juvenile (5-week-old) mice. The arrows indicate typical terminal end buds; LN, lymph node. (B) The result of morphometric analysis of the average number of TEBs at 5 weeks and (C) of branches per gland at 11 weeks. At least 10 animals of each genotype were analyzed for each time point. In the absence of one copy of Lrp6, the number of TEBs is reduced by 33% (p = 1.3×10−6, 2-tailed t test assuming unequal variances), and the number of branches per gland is reduced by 17% (p = 8.4×10−3, 2-tailed t test assuming unequal variances) compared with Lrp6+/+ littermate controls. (D) Mammary whole mounts containing ductal colonization originating from transplanted Lrp6+/+ or Lrp6+/− mammary epithelial cells. Also shown is a transplantation control whose inguinal fat pads were cleared of endogenous epithelium but not injected with mammary cells. (E) The inguinal mammary gland from an adult Lrp6+/−;Lrp5−/− female. The mammary gland contains a fat pad and a nipple with associated epithelium but lacks a ductal tree. Box indicates the nipple epithelium.


We next tested whether the Lrp6+/− ductal phenotype would become more or less apparent after transplantation of epithelial cells into wild-type mammary glands. For this purpose we transplanted 5,000 Lrp6+/− or Lrp6+/+ mammary epithelial cells into the cleared fat pads of 21-day-old immune-compromised Rag2-deficient females. Out-growths were found in 5/8 and 6/8 fat pads transplanted with Lrp6+/− and Lrp6+/+ mammary epithelial cells, respectively. The branching morphology was similar in host fat pads six weeks after surgery regardless of transplant genotype (Fig. 3D). None of the 4 Rag2-deficient control mice whose fat pads (n = 8) were cleared but not injected with mammary epithelial cells contained ductal out-growths, confirming our ability to successfully clear the mammary fat pad (Fig. 3D).

We also examined the effect of compound mutations of Lrp6 and Lrp5. While embryos of the Lrp6−/−;Lrp5−/− and Lrp6−/−;Lrp5+/− genotypes die during embryogenesis, some Lrp6+/−;Lrp5−/− mice live into adulthood. Lrp6+/−;Lrp5−/− mice have limb deformities and 80% die shortly after birth, but surviving pups have a normal life span and are fertile [16], [17]. We dissected the mammary glands from formalin-fixed Lrp6+/−;Lrp5−/− female carcasses previously studied for their bone phenotype. Although nipples and normal size fat pads were visible upon dissection, none of the 5 analyzed animals had ductal tree outgrowths in any of their 10 mammary glands (Fig. 3E).

MMTV-Wnt1 expression induces epithelial proliferation in Lrp6−/− and Lrp6+/− mice

Female mice that express Wnt1 under the mammary-specific MMTV promoter reproducibly develop mammary adenocarcinomas within one year [26]. The tumors develop in a context of widespread hyperplasia that is noticeable as early as E18.5. To test whether transgenic expression of Wnt1 could induce ductal side-branching in Lrp6−/− embryos and to determine the requirement for Lrp6 in Wnt1-induced tumorigenesis, we intercrossed Lrp6+/− and MMTV-Wnt1 mice. We found that transgenic expression of Wnt1 partially rescued the Lrp6−/−ductal phenotype at E18.5 and induced sprout elongation and side-branching (Fig. 4A). The inguinal mammary epithelial tree of MMTV-Wnt1;Lrp6+/+ (n = 6) and MMTV-Wnt1;Lrp6−/− (n = 4) embryos contained on average 10 and 4 end buds, respectively. The MMTV-Wnt1;Lrp6−/− mammary nipples and fat pads were still abnormally small. Furthermore, no obvious reduction in mammary hyperplasia was observed, and tumor onset was only slightly delayed in adult MMTV-Wnt1;Lrp6+/− females (p = 0.08) (Fig. 4B–C). Histopathological examination showed that all tumors, regardless of Lrp6 genotype, were moderately differentiated alveolar mammary adenocarcinomas (Fig. 4D).


Figure 4. Wnt1-induced mammary tumorigenesis in Lrp6+/− females.

Shown in (A-B) are representative carmine stained skin pads and mammary whole mounts. (A) Skin pads collected from E18.5 MMTV-Wnt1;Lrp6+/+ and MMTV-Wnt1;Lrp6−/− embryos. (B) Mammary whole mounts collected from adult MMTV-Wnt1;Lrp6+/+ and MMTV-Wnt1;Lrp6+/− females. (C) The percentages of MMTV-Wnt1;Lrp6+/+ (n = 12) and MMTV-Wnt1;Lrp6+/− mice (n = 13) that were tumor-free (as determined by weekly visual inspection and/or palpation) were plotted against the age when tumors were found. (D) Standard histopathological evaluation showed that all Lrp6+/+ and Lrp6+/− MMTV-Wnt1 tumors are moderately differentiated alveolar mammary adenocarcinomas.


Increased Lrp6 expression in human basal-like breast cancer

Global gene expression analyses of human breast cancers have identified four major tumor subtypes and a normal breast tissue group [27][29]. Two subtypes are estrogen receptor (ER)–negative and have poor patient outcomes: one of these two subtypes is defined by the high expression of HER2, and the other shows characteristics of basal/myoepithelial cells (basal-like). The remaining two subtypes, luminal subtype A or B, are ER-positive and Keratin 8/18–positive. We looked at the expression pattern of Lrp6 in two published transcriptome profiles of breast cancer. The first study, led by Livingston and Ganesan at Harvard Medical School, contained 45 samples (18 Basal-like, 20 non-Basal, and 7 Normal) [30] (Fig. 5A) and the second, led by Perou at the University of North Carolina, contained 213 samples (64 Basal-like, 30 HER+, 70 Luminal A, 31 Luminal B, and 18 Normal Breast-like) [31] (Fig. 5B). We found that increased expression of Lrp6 was associated with basal-like breast cancer (p = 1.8×10–4, p = 9.6×10–5) (Fig. 5A–B). In fact, a fraction of samples within the basal-like subgroup of both studies expressed levels of Lrp6 not seen in any of the other subgroups or the normal controls. Interestingly, we also found a correlation between Lrp5 expression and basal-like breast cancer (p = 4.6×10–3, p = 3.7×10–3) (data not shown).


Figure 5. Increased Lrp6 expression in basal-like human breast cancer.

The relative expression of Lrp6 in breast cancer samples analyzed by Affymetrix and organized into defined subgroups. Each dot represents the relative expression of Lrp6 in one tumor sample. (A) Expression data was obtained from [30]. Normal includes samples obtained from normal breast tissue. (B) Expression data was obtained from [31]. Normal Breast-like includes samples obtained from normal and cancerous breast tissue that exhibited expression profiles similar to that of normal breast tissue. A subset of breast cancers within the basal-like subgroup of both studies exhibit increased expression of Lrp6.



Wnt signaling pathways play essential roles at multiple steps of animal development, including embryonic induction, organogenesis, and adult tissue homeostasis. The binding of Wnt ligands to a receptor complex composed of one Frizzled (Fzd) protein and either LRP5 or LRP6 initiates the Wnt/β-catenin cascade. At the cellular level, Wnt/β-catenin signaling regulates a broad range of functions, including the self-renewal and differentiation of stem cells. We have previously shown that Lrp5 is critical for mammary ductal stem cell activity: its loss is associated with impaired mammary gland development and delayed Wnt1-induced mammary tumorigenesis [21]. Here, we show that Lrp6 is also required for normal mammary gland development. Loss of Lrp6 impairs embryonic mammary development, evident by abnormal mammary placode development at E12.5 and the absence of ductal branching and fat pad development at E18.5 (Fig. 2A–D). Furthermore, postnatal mammary development is affected in Lrp6 heterozygote females: the number of TEBs and ductal branches are reduced in juvenile and adult mice, respectively (Fig. 3A–C). Although it is not yet clear whether Lrp6 is required for ductal stem cell activity, we found that Lrp6 is expressed by epithelial cells within the basal cell layer that also express stem cell markers (Fig. 1B–D). Finally, an increased expression of Lrp6 is associated with human basal-like breast cancer (Fig. 5A–B). Taken together with our previous study, our results show that both Lrp5 and Lrp6 play essential roles in the mammary gland development and cannot fully compensate for each other's loss.

The initial stages of mammary development are hormone-independent, depending instead on reciprocal signaling between the epithelium and the mesenchyme (reviewed in [32][34]). Mammary gland development begins at about embryonic day 10.5 with the appearance of the mammary lines. In response to signals from the underlying mesenchyme, the mammary lines give rise to five pairs of lens-shaped mammary placodes that subsequently invaginate into the underlying dermal mesenchyme, forming mammary buds. In females at E15.5, the buds elongate and form a mammary sprout that extends towards the fat pad precursor mesenchyme. Mammary nipples are formed around E16.5. Meanwhile the epithelial sprout branches into the fat pad precursor mesenchyme, resulting in the formation of a rudimentary ductal tree prepared to respond to hormonal cues at puberty.

Studies using Wnt reporter gene mouse strains have shown that activation of the Wnt/β-catenin signaling pathway along the mammary lines coincides with the initiation of mammary morphogenesis and subsequently localizes to the mammary placodes, buds, and rudimentary ductal tree [21], [35], [36]. Furthermore, Wnt signaling appears to be required for embryonic mammary development: embryos deficient for Lef1 fail to develop/maintain their mammary placodes, and embryos that express the Wnt inhibitor Dkk1 in developing epithelium fail to form mammary placodes [37], [38]. Dkk1 inhibits the Wnt signaling pathway by binding to (and presumably inactivating) Lrp5 and Lrp6 [39]. In agreement, embryos lacking Lrp5 exhibit reduced Wnt/β-catenin signaling and have significantly smaller mammary placodes than littermate wild-type controls [21]. Despite the placode phenotype, the rudimentary ductal tree and fat pad develop normally in Lrp5−/− embryos.

At E12.5, the phenotype of Lrp6−/− embryos is similar to that of Lrp5−/− embryos, the mammary placodes are smaller, abnormally developed, and contain few cells with activated Wnt/β-catenin signaling relative to wild-type controls (Fig. 2C–D). However, in contrast to Lrp5−/− embryos, the rudimentary ductal tree fails to develop in Lrp6−/−embryos (Fig. 2A). It is not clear if this phenotype is due to an inadequacy of the mammary epithelium or/and the fat pad. Signals from the fat pad mesenchyme play a central role for ductal elongation and branching and may be diminished in the absence of Lrp6 [32][34]. Lrp6 is normally expressed both in the mammary epithelium and fat pad, and the loss of Lrp6 is associated with abnormal development of both compartments. The MMTV-Wnt1;Lrp6 cross showed that Lrp6−/− mammary epithelium is not incapable of further development, since transgenic expression of MMTV-Wnt1 produced sprout elongation and branching despite the presence of underdeveloped fat pads (Fig. 4A). This suggests that the dose of Wnt/β-catenin signaling within the mammary epithelium is critical and can determine the degree of embryonic ductal development. In further support of this, Lrp6+/−;Lrp5−/− female mice fail to develop mammary ducts (Fig. 3E).

We have previously shown that Lrp5 is required for Wnt1-induced mammary tumorigenesis [21]. Tumor onset is dramatically delayed in MMTV-Wnt1;Lrp5−/− and MMTV-Wnt1;Lrp5+/− females. The effect of Lrp6 heterozygosity was much less pronounced. The average time of tumor onset was delayed by 6 and 17 weeks in Lrp6+/− and Lrp5+/− mice, respectively (Fig. 4C and [21]). Lrp6 heterozygosity slightly delayed the time at which tumors first appeared, but the rate of tumor onset was then similar between Lrp6+/− and Lrp6+/+ females (Fig. 4C). Consistent with this, we saw no reduction in mammary hyperplasia in adult MMTV-Wnt1;Lrp6+/− females (Fig. 4B). Relatively little is known of the ligand-receptor specificity exhibited by different Wnts, Fzds, and LRPs in Wnt signaling. However, our results suggest that Lrp5 plays a pivotal role over Lrp6 in transmitting oncogenic Wnt signals in the MMTV-Wnt1 mammary tumor model.

Wnt/β-catenin signaling is a key regulator of embryonic and somatic stem cells [9], [10]. In the adult mouse, Wnt/β-catenin signaling has been shown to regulate a number of epithelial stem cell compartments, including those of the skin, gut, and mammary gland [40][44]. Mammary epithelial cells with stem cell activity, i.e., cells that can develop a functional ductal tree in single cell transplantation experiments, can be identified by FACS [23], [45]. These cells typically express moderate and high levels of the cell surface markers CD24 and CD49f, respectively [23]. Interestingly, most Lrp6-expressing mammary epithelial cells exhibited this expression pattern (Fig. 1C–D). Furthermore, mammary stem cells are presumed to reside within the basal cell layer of the mature mammary ducts [23], [46], [47], and this is where Lrp6-expressing cells primarily were identified (Fig. 1B). We also found that human basal-like breast cancers are associated with increased Lrp6 expression, suggesting that these tumors may be enriched with Lrp6-expressing cells. Subpopulations of cancer cells with stem cell properties are especially frequent within basal-like breast cell lines and show increased tumorigenic and invasive potential [48], [49]. Whether Lrp6 is required for ductal stem cell activity remains to be determined, as does the role of Lrp6-mediated Wnt signaling in the mammary fat pad. Development of conditional mouse models for Lrp6 and Lrp5 deletion will aid in the understanding of the specific roles of these proteins in mammary gland development and tumorigenesis. This is particularly important because Wnt/β-catenin signaling is often activated in human breast cancer. At least 50% of human breast cancers exhibit nuclear/cytoplasmic β-catenin, and aberrant activation of the pathway at the receptor level is common [9], [50][52]. Hence, therapeutic interventions targeting LRP5 and/or LRP6 could be useful in treating some types of breast cancer, particularly the basal-like class for which few, if any, effective treatments exist.

Materials and Methods

Mouse strains and husbandry

Lrp6 (C57Bl/6J) knock-out mice, as well as BAT-gal (FVB/N) and MMTV-Wnt1 (FVB/N) transgenic mice, have been previously described [13], [25], [26]. PCR-based strategies were used to genotype these mice (details available upon request). All experiments performed were approved in advance by the Van Andel Research Institute Institutional Animal Care and Use Committee. To assay the appearance of mammary tumors, the mice were inspected three times a week and were euthanized when tumors appeared.

Mammary gland morphogenesis

Whole mounts were prepared as described [53]. Briefly, inguinal mammary glands were dissected, fixed overnight in Carnoy formula (6:3:1 ratio of ethanol:chloroform:glacial acetic acid), rehydrated, and stained overnight in Carmine alum stain. The stained glands were dehydrated, cleared in xylene, and stored in Methyl Salicylate. After whole-mount pictures had been taken, the tissues were embedded in paraffin for sectioning. Sections (5 µm) were rehydrated and counterstained with H&E.

Oil red O staining

Ventral skin pads were placed in propylene glycol for 2 min and then in Oil red O stain heated to 60°C for 6 min, followed by 85% propylene glycol in distilled water for 1 min, and lastly rinsed twice in water.

X-gal staining

Lrp6+/− and Lrp6+/+ (negative control) mammary glands and 12.5-day-old embryos were isolated and fixed in 0.25% glutaraldehyde, 2% formaldehyde, 5 mM EGTA, and 2 mM MgCl2 in PBS pH 7.4 at 4°C. Mammary glands were fixed for 2 h; embryos for 1 h. Glands and embryos were then rinsed twice in 2 mM MgCl2, 0.1% sodium deoxycholate, and 0.2% NP40 in PBS at room temperature for 1 h and then were stained in X-gal buffer (1 mg/ml X-gal, 2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% NP-40, 5 mM Fe3(CN)6, 5 mM Fe4(CN)6 in PBS) at 30°C. Lrp6+/− mammary glands were stained overnight; BATgal transgenic embryos were stained for 20 min. The whole mounts were then rinsed in PBS, dehydrated, and cleared in xylene. After whole-mount pictures had been taken, the tissues were immediately embedded in paraffin for sectioning. Sections (5 µm) were counterstained with 0.1% nuclear fast red or eosin. A minimum of three animals per genotype and time point were analyzed.

Primary mammary epithelial cell isolation

Mammary glands were dissected and minced with scissors, then the cells were dissociated for 8 h at 37°C in EpiCult-B with 5% fetal bovine serum, 300 units/ml collagenase, and 100 units/ml hyaluronidase. After vortexing and lysis of the red blood cells in NH4Cl, a single-cell suspension was obtained by sequential dissociation of the fragments by gentle pipetting for 1–2 min in 0.25% trypsin and then for 2 min in 5 mg/ml Dispase II plus 0.1 mg/ml DNase I, followed by filtration through a 40-mm mesh. All reagents were from StemCell Technologies Inc.

Mammary transplantation assays

Viable mammary epithelial cells collected from 3-month-old Lrp6+/− (n = 5) and Lrp6+/+ (n = 3) virgin female mice were counted on a hemocytometer, suspended at the desired concentration in 1:1 PBS:Matrigel (BD Biosciences) together with 0.5% trypan blue loading dye, and kept on ice until transplantation. Cells were injected in a total volume of 10 µl into contralateral cleared fat pads of the #4 mammary glands of 21-day-old female Rag2−/− mice using a Hamilton syringe [54]. Six or 12 weeks after transplantation, the fat pads were dissected, processed, and stained with carmine as described above.

Fluorescence-activated cell sorting

Mammary epithelial cells were isolated as described above. The Mouse Mammary Stem Cell Enrichment Kit from StemCell Technologies was used to obtain CD45, Ter119, and CD31 triple-negative cell suspensions labeled with CD24 and CD49f. Briefly, mammary epithelial cells were first incubated in a cocktail of biotinylated CD45, Ter119, and CD31 antibodies, and then were exposed to a biotin selection cocktail and removed using magnetic nanoparticles. The remaining cells were labeled with DDAOG (10 µm), CD24-PE, and CD49f-FITC for 30 min on ice, then washed and resuspended in Hanks with 2% FBS and kept on ice. Live cells were discriminated by propidium iodine exclusion. Cell sorting and analysis was done by using the BD FACSCalibur Flow Cytometer and Cell quest 5.2.1 software, respectively (BD Biosciences). The FACS analysis described above was repeated twice and included mammary epithelial cells collected from 4 Lrp6+/− and 5 Lrp6+/+ females.

Expression profiling

Processed expression chip used in the GSE3744 dataset contained multiple probes that mapped to LRP6. Therefore in this dataset, the average LRP6 expression value was computed for each sample and used in subsequent analysis. In the GSE3165 dataset, three related expression chips were used and a single LRP6 probe (NM_002336) was present across the majority of the chips. Therefore, the expression value derived from the NM_00236 probe was used in subsequent analysis. Within each dataset, the LRP6 expression values were partitioned into groups based on tumor subtype and differences in expression between the basal-like and non-basal like samples evaluated using a two-sided Welsh's t-test.


We thank the Van Andel Research Institute's vivarium staff for outstanding animal husbandry.

Author Contributions

Conceived and designed the experiments: CL BOW. Performed the experiments: CL CZ NCE RW. Analyzed the data: CL CZ NCE RW KD BOW. Contributed reagents/materials/analysis tools: CL KD KAF BOW. Wrote the paper: CL KAF BOW.


  1. 1. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387–398.
  2. 2. Gordon MD, Nusse R (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281: 22429–22433.
  3. 3. Seifert JR, Mlodzik M (2007) Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 8: 126–138.
  4. 4. Slusarski DC, Pelegri F (2007) Calcium signaling in vertebrate embryonic patterning and morphogenesis. Dev Biol 307: 1–13.
  5. 5. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691–701.
  6. 6. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480.
  7. 7. Grigoryan T, Wend P, Klaus A, Birchmeier W (2008) Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 22: 2308–2341.
  8. 8. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843–850.
  9. 9. Lindvall C, Bu W, Williams BO, Li Y (2007) Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 3: 157–168.
  10. 10. Nusse R (2008) Wnt signaling and stem cell control. Cell Res 18: 523–527.
  11. 11. Cadigan KM (2008) Wnt-beta-catenin signaling. Curr Biol 18: R943–947.
  12. 12. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, et al. (2000) arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 407: 527–530.
  13. 13. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC (2000) An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407: 535–538.
  14. 14. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, et al. (2000) LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530–535.
  15. 15. Holmen SL, Salic A, Zylstra CR, Kirschner MW, Williams BO (2002) A novel set of Wnt-Frizzled fusion proteins identifies receptor components that activate beta -catenin-dependent signaling. J Biol Chem 277: 34727–34735.
  16. 16. Kelly OG, Pinson KI, Skarnes WC (2004) The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development 131: 2803–2815.
  17. 17. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, et al. (2004) Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19: 2033–2040.
  18. 18. Patel MS, Karsenty G (2002) Regulation of bone formation and vision by LRP5. N Engl J Med 346: 1572–1574.
  19. 19. Fujino T, Asaba H, Kang MJ, Ikeda Y, Sone H, et al. (2003) Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A 100: 229–234.
  20. 20. Xia CH, Liu H, Cheung D, Wang M, Cheng C, et al. (2008) A model for familial exudative vitreoretinopathy caused by LPR5 mutations. Hum Mol Genet 17: 1605–1612.
  21. 21. Lindvall C, Evans NC, Zylstra CR, Li Y, Alexander CM, et al. (2006) The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem 281: 35081–35087.
  22. 22. Tung CH, Zeng Q, Shah K, Kim DE, Schellingerhout D, et al. (2004) In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res 64: 1579–1583.
  23. 23. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, et al. (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439: 993–997.
  24. 24. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, et al. (2006) Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 98: 1011–1014.
  25. 25. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, et al. (2003) Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A 100: 3299–3304.
  26. 26. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55: 619–625.
  27. 27. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
  28. 28. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874.
  29. 29. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418–8423.
  30. 30. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121–132.
  31. 31. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
  32. 32. Veltmaat JM, Mailleux AA, Thiery JP, Bellusci S (2003) Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. Differentiation 71: 1–17.
  33. 33. Howard B, Ashworth A (2006) Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet 2: e112.
  34. 34. Robinson GW (2007) Cooperation of signalling pathways in embryonic mammary gland development. Nat Rev Genet 8: 963–972.
  35. 35. Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, et al. (2004) Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 131: 4819–4829.
  36. 36. Boras-Granic K, Chang H, Grosschedl R, Hamel PA (2006) Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland. Dev Biol 295: 219–231.
  37. 37. van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, et al. (1994) Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 8: 2691–2703.
  38. 38. Andl T, Reddy ST, Gaddapara T, Millar SE (2002) WNT signals are required for the initiation of hair follicle development. Dev Cell 2: 643–653.
  39. 39. Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25: 7469–7481.
  40. 40. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, et al. (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19: 379–383.
  41. 41. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W (2001) beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105: 533–545.
  42. 42. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650–653.
  43. 43. Liu BY, McDermott SP, Khwaja SS, Alexander CM (2004) The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A 101: 4158–4163.
  44. 44. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, et al. (2009) MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS ONE 4: e4537.
  45. 45. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, et al. (2006) Generation of a functional mammary gland from a single stem cell. Nature 439: 84–88.
  46. 46. Smith GH, Boulanger CA (2003) Mammary epithelial stem cells: transplantation and self-renewal analysis. Cell Prolif 36: (Suppl 1)3–15.
  47. 47. Smalley M, Ashworth A (2003) Stem cells and breast cancer: A field in transit. Nat Rev Cancer 3: 832–844.
  48. 48. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, et al. (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59.
  49. 49. Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791–799.
  50. 50. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, et al. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97: 4262–4266.
  51. 51. Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, et al. (2006) Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol 19: 556–563.
  52. 52. Bjorklund P, Svedlund J, Olsson AK, Akerstrom G, Westin G (2009) The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS ONE 4: e4243.
  53. 53. Ip MM, Asch BB (2000) Methods in Mammary Gland Biology and Breast Cancer Research. New York: Springer.
  54. 54. Kordon EC, Smith GH (1998) An entire functional mammary gland may comprise the progeny from a single cell. Development 125: 1921–1930.